These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9777182)

  • 1. Tardive dyskinesia and serum iron indices.
    Wirshing DA; Bartzokis G; Pierre JM; Wirshing WC; Sun A; Tishler TA; Marder SR
    Biol Psychiatry; 1998 Sep; 44(6):493-8. PubMed ID: 9777182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.
    Sachdev P; Hume F; Toohey P; Doutney C
    Acta Psychiatr Scand; 1996 Jun; 93(6):451-9. PubMed ID: 8831862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low plasma iron status and akathisia.
    Barton A; Bowie J; Ebmeier K
    J Neurol Neurosurg Psychiatry; 1990 Aug; 53(8):671-4. PubMed ID: 1976763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal involuntary movements in patients on long-acting neuroleptics.
    Oyewumi LK; Lapierre YD; Gray R; Batth S; Gelfand R
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):719-23. PubMed ID: 6141614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum iron and ferritin in acute neuroleptic akathisia.
    Hofmann M; Seifritz E; Botschev C; Kräuchi K; Müller-Spahn F
    Psychiatry Res; 2000 Apr; 93(3):201-7. PubMed ID: 10760378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Tan YL; Zhou DF; Zhang XY
    Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactions.
    Spina E; Ancione M; Di Rosa AE; Artemisia A; Natoli C; Caputi AP
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Sep; 18(5):891-8. PubMed ID: 7972859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentration of depot neuroleptics in tardive dyskinesia.
    Fairbairn AF; Rowell FJ; Hui SM; Hassanyeh F; Robinson AJ; Eccleston D
    Br J Psychiatry; 1983 Jun; 142():579-83. PubMed ID: 6882980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.